Norges Bank Purchases Shares of 540,134 Illumina, Inc. $ILMN

Norges Bank acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 540,134 shares of the life sciences company’s stock, valued at approximately $70,844,000.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of Illumina by 17.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after buying an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co purchased a new position in shares of Illumina during the 3rd quarter valued at about $2,319,000. Caprock Group LLC purchased a new position in shares of Illumina during the 3rd quarter valued at about $1,479,000. Capital World Investors lifted its position in shares of Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after buying an additional 3,331,542 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ILMN shares. JPMorgan Chase & Co. boosted their price target on Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Piper Sandler lowered their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Barclays boosted their price target on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $138.38.

Illumina Stock Down 3.4%

NASDAQ ILMN opened at $162.32 on Friday. The stock’s 50 day moving average is $137.75 and its 200 day moving average is $133.57. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $82.44 and a 12 month high of $177.22. The stock has a market cap of $24.56 billion, a PE ratio of 29.51, a P/E/G ratio of 3.04 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the company posted $0.97 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the sale, the director owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. The trade was a 7.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $98,400.00. Following the completion of the sale, the insider directly owned 21,568 shares in the company, valued at approximately $3,450,880. The trade was a 2.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,002,371 shares of company stock worth $155,472,900. 2.90% of the stock is owned by insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.